HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
Can T‑DXd be used in HER2 ultra‑low or null TNBC?
Dr Huppert cites DAISY and real‑world experience supporting T‑DXd activity even in HER2 null/ultra‑low patients.
Play episode from 24:25
Transcript
